MCL Literature Feed

This case report describes an extremely rare presentation of MCL as a polypoid endotracheal mass causing dyspnea, highlighting lymphoma as a differential diagnosis for airway obstruction.

Identifies splicing factors SRSF1, hnRNP F, and PTBP1 as drivers of MCL aggressiveness and potential therapeutic targets, whose high expression with MYC predicts poor survival.

This case report links the next-generation BTKi orelabrutinib to multiple skin cancers, suggesting this toxicity may be a class effect and reinforcing the need for dermatologic surveillance.

This case report details MCL transformation into CD19-negative classic Hodgkin lymphoma after CAR-T, a novel resistance mechanism driven by immunotherapeutic pressure and lineage plasticity in a high-risk patient.

This review summarizes the MCL treatment evolution from chemoimmunotherapy and transplant to targeted agents (BTKi) and immunotherapies (CAR-T, bispecifics), emphasizing a future of personalized, genomics-guided care.

A novel gene-editing method creates safer allogeneic CAR-T cells, potentially offering a more accessible 'off-the-shelf' cellular therapy option for MCL patients.

This case report describes a rare primary cutaneous presentation of mantle cell lymphoma, highlighting the need to consider MCL in the differential diagnosis of new skin masses.

This review summarizes the rapid clinical integration of T-cell engaging therapies (CAR-T, bispecifics) for B-NHL, including MCL, and outlines future strategies like earlier use and novel constructs.

A novel single-cell method combining biophysical and transcriptomic data identifies distinct MCL subpopulations, offering new insights into tumor heterogeneity and potential therapeutic resistance.

Acquired MYC rearrangements were found in 43% of ibrutinib-resistant MCL tumors, identifying a key genomic alteration that drives intrinsic resistance and may serve as a critical biomarker.

Pretargeted anti-CD20 radioimmunotherapy safely intensifies BEAM conditioning before autologous transplant in high-risk B-cell lymphomas, including MCL, offering a feasible new consolidation strategy.

This case report describes a rare relapse of mantle cell lymphoma presenting as an isolated laryngeal mass, emphasizing the importance of considering unusual sites of recurrence in MCL patients.

This real-world database analysis shows MCL patients treated at academic centers had significantly longer overall survival and higher trial participation, highlighting a major care disparity versus community settings.

Real-world data from older Chinese MCL patients shows BTKi-based regimens and maintenance therapy significantly improve survival, validating these strategies for this specific, understudied elderly population.

In newly diagnosed MCL, higher total lymphocyte and B-cell counts in the bone marrow correlated with a lower percentage of disease progression, suggesting a potential prognostic flow cytometry biomarker.

Radiotherapy for localized orbital MCL achieves excellent long-term cancer-specific survival (83% at 15 years), supporting its use as a primary treatment, especially for elderly or frail patients.

This indirect treatment comparison provides the first comparative evidence between zanubrutinib and acalabrutinib for relapsed/refractory MCL, guiding clinical selection in the absence of a head-to-head trial.

This review summarizes the evolution of BTK inhibitors, from covalent to reversible agents, to overcome resistance and toxicity, highlighting their central role in current and future MCL therapies.

This first reported case of mantle cell lymphoma with hypereosinophilia demonstrates a rare paraneoplastic presentation where eosinophil counts normalized following successful immunochemotherapy, expanding the disease's clinical spectrum.

This case report identifies chronic enteroviral meningoencephalitis as a severe neurotoxicity of rituximab maintenance in MCL, demonstrating successful resolution with intravenous immunoglobulins (IVIg) and fluoxetine.

This review of BCL-2 inhibitors in other indolent lymphomas provides context for their use in MCL, summarizing preclinical and clinical data supporting this therapeutic class in B-cell malignancies.

This review summarizes preclinical nanocarrier strategies designed to improve ibrutinib's bioavailability and targeted delivery, potentially enhancing efficacy and reducing off-target toxicity for MCL patients in the future.

A systematic review finds MCL has particularly high uptake on CXCR4-targeted [68Ga]Ga-Pentixafor PET, suggesting its utility for staging and response assessment, potentially superior to FDG-PET.

This study confirms a rare DLBCL subtype with CCND1 rearrangement, molecularly distinct from MCL by its SOX11-negativity and DLBCL-like mutations, posing a critical diagnostic and therapeutic challenge.

In the frontline MANTLE-FIRST study, fitness status and time to first progression (PFS1) were identified as key prognostic factors for elderly MCL patients, impacting subsequent outcomes.

In the BRUIN study, relapsed/refractory MCL patients previously treated with a BTKi maintained or improved quality of life and symptoms on pirtobrutinib, supporting its favorable long-term tolerability.

Genomic analysis reveals MCL relapse is driven by pre-existing resistant clones from diagnosis, not new mutations, emphasizing the need for deep upfront responses to eradicate these subclones.

A preclinical multi-modal profiling platform integrating genomics, in vitro drug screening, and PDX models identified personalized therapies for BTKi-relapsed/refractory MCL, guiding treatment beyond single gene alterations.

Pirtobrutinib-tolerant MCL persister cells survive via a reversible TCA cycle metabolic switch, presenting a novel metabolic vulnerability to target and prevent drug resistance.

White-centered retinal hemorrhages (Roth spots) can be the initial presenting sign of an otherwise hidden mantle cell lymphoma, highlighting an important and unusual diagnostic clue for clinicians.